Literature DB >> 19028582

Passive immunotherapy rapidly increases structural plasticity in a mouse model of Alzheimer disease.

Tara L Spires-Jones1, Matthew L Mielke, Anete Rozkalne, Melanie Meyer-Luehmann, Alix de Calignon, Brian J Bacskai, Dale Schenk, Bradley T Hyman.   

Abstract

Senile plaque-associated changes in neuronal connectivity such as altered neurite trajectory, dystrophic swellings, and synapse and dendritic spine loss are thought to contribute to cognitive dysfunction in Alzheimer's disease and mouse models. Immunotherapy to remove amyloid beta is a promising therapy that causes recovery of neurite trajectory and dystrophic neurites over a period of days. The acute effects of immunotherapy on neurite morphology at a time point when soluble amyloid has been cleared but dense plaques are not yet affected are unknown. To examine whether removal of soluble amyloid beta (Abeta) has a therapeutic effect on dendritic spines, we explored spine dynamics within 1 h of applying a neutralizing anti Abeta antibody. This acute treatment caused a small but significant increase in dendritic spine formation in PDAPP brain far from plaques, without affecting spine plasticity near plaques or average dendritic spine density. These data support the hypothesis that removing toxic soluble forms of amyloid-beta rapidly increases structural plasticity possibly allowing functional recovery of neural circuits.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19028582      PMCID: PMC2672591          DOI: 10.1016/j.nbd.2008.10.011

Source DB:  PubMed          Journal:  Neurobiol Dis        ISSN: 0969-9961            Impact factor:   5.996


  39 in total

Review 1.  Toward a comprehensive theory for Alzheimer's disease. Hypothesis: Alzheimer's disease is caused by the cerebral accumulation and cytotoxicity of amyloid beta-protein.

Authors:  D J Selkoe
Journal:  Ann N Y Acad Sci       Date:  2000       Impact factor: 5.691

2.  Peripherally administered antibodies against amyloid beta-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease.

Authors:  F Bard; C Cannon; R Barbour; R L Burke; D Games; H Grajeda; T Guido; K Hu; J Huang; K Johnson-Wood; K Khan; D Kholodenko; M Lee; I Lieberburg; R Motter; M Nguyen; F Soriano; N Vasquez; K Weiss; B Welch; P Seubert; D Schenk; T Yednock
Journal:  Nat Med       Date:  2000-08       Impact factor: 53.440

3.  Behavioral disturbances in transgenic mice overexpressing the V717F beta-amyloid precursor protein.

Authors:  J C Dodart; H Meziane; C Mathis; K R Bales; S M Paul; A Ungerer
Journal:  Behav Neurosci       Date:  1999-10       Impact factor: 1.912

4.  Neuroanatomical abnormalities in behaviorally characterized APP(V717F) transgenic mice.

Authors:  J C Dodart; C Mathis; J Saura; K R Bales; S M Paul; A Ungerer
Journal:  Neurobiol Dis       Date:  2000-04       Impact factor: 5.996

5.  Plaque-induced abnormalities in neurite geometry in transgenic models of Alzheimer disease: implications for neural system disruption.

Authors:  R Le; L Cruz; B Urbanc; R B Knowles; K Hsiao-Ashe; K Duff; M C Irizarry; H E Stanley; B T Hyman
Journal:  J Neuropathol Exp Neurol       Date:  2001-08       Impact factor: 3.685

6.  A learning deficit related to age and beta-amyloid plaques in a mouse model of Alzheimer's disease.

Authors:  G Chen; K S Chen; J Knox; J Inglis; A Bernard; S J Martin; A Justice; L McConlogue; D Games; S B Freedman; R G Morris
Journal:  Nature       Date:  2000 Dec 21-28       Impact factor: 49.962

7.  A beta peptide immunization reduces behavioural impairment and plaques in a model of Alzheimer's disease.

Authors:  C Janus; J Pearson; J McLaurin; P M Mathews; Y Jiang; S D Schmidt; M A Chishti; P Horne; D Heslin; J French; H T Mount; R A Nixon; M Mercken; C Bergeron; P E Fraser; P St George-Hyslop; D Westaway
Journal:  Nature       Date:  2000 Dec 21-28       Impact factor: 49.962

8.  Immunization reverses memory deficits without reducing brain Abeta burden in Alzheimer's disease model.

Authors:  Jean-Cosme Dodart; Kelly R Bales; Kimberley S Gannon; Stephen J Greene; Ronald B DeMattos; Chantal Mathis; Cynthia A DeLong; Su Wu; Xin Wu; David M Holtzman; Steven M Paul
Journal:  Nat Neurosci       Date:  2002-05       Impact factor: 24.884

9.  Non-Fc-mediated mechanisms are involved in clearance of amyloid-beta in vivo by immunotherapy.

Authors:  Brian J Bacskai; Stephen T Kajdasz; Megan E McLellan; Dora Games; Peter Seubert; Dale Schenk; Bradley T Hyman
Journal:  J Neurosci       Date:  2002-09-15       Impact factor: 6.167

10.  Reversible memory loss in a mouse transgenic model of Alzheimer's disease.

Authors:  Linda A Kotilinek; Brian Bacskai; Marcus Westerman; Takeshi Kawarabayashi; Linda Younkin; Bradley T Hyman; Steven Younkin; Karen H Ashe
Journal:  J Neurosci       Date:  2002-08-01       Impact factor: 6.167

View more
  39 in total

1.  Novel amyloid-beta specific scFv and VH antibody fragments from human and mouse phage display antibody libraries.

Authors:  M Medecigo; K Manoutcharian; V Vasilevko; T Govezensky; M E Munguia; B Becerril; A Luz-Madrigal; L Vaca; D H Cribbs; G Gevorkian
Journal:  J Neuroimmunol       Date:  2010-05-06       Impact factor: 3.478

2.  Activation of glycogen synthase kinase-3 beta mediates β-amyloid induced neuritic damage in Alzheimer's disease.

Authors:  B DaRocha-Souto; M Coma; B G Pérez-Nievas; T C Scotton; M Siao; P Sánchez-Ferrer; T Hashimoto; Z Fan; E Hudry; I Barroeta; L Serenó; M Rodríguez; M B Sánchez; B T Hyman; T Gómez-Isla
Journal:  Neurobiol Dis       Date:  2011-09-13       Impact factor: 5.996

3.  Oligomeric amyloid beta associates with postsynaptic densities and correlates with excitatory synapse loss near senile plaques.

Authors:  Robert M Koffie; Melanie Meyer-Luehmann; Tadafumi Hashimoto; Kenneth W Adams; Matthew L Mielke; Monica Garcia-Alloza; Kristina D Micheva; Stephen J Smith; M Leo Kim; Virginia M Lee; Bradley T Hyman; Tara L Spires-Jones
Journal:  Proc Natl Acad Sci U S A       Date:  2009-02-19       Impact factor: 11.205

Review 4.  The intersection of amyloid beta and tau at synapses in Alzheimer's disease.

Authors:  Tara L Spires-Jones; Bradley T Hyman
Journal:  Neuron       Date:  2014-05-21       Impact factor: 17.173

Review 5.  Amyloid-beta immunotherapy for Alzheimer's disease.

Authors:  H J Fu; B Liu; J L Frost; C A Lemere
Journal:  CNS Neurol Disord Drug Targets       Date:  2010-04       Impact factor: 4.388

6.  Estrogen-induced signaling attenuates soluble Aβ peptide-mediated dysfunction of pathways in synaptic plasticity.

Authors:  Shaun M Logan; Saumyendra N Sarkar; Zhang Zhang; James W Simpkins
Journal:  Brain Res       Date:  2011-01-22       Impact factor: 3.252

7.  Beneficial effect of human anti-amyloid-beta active immunization on neurite morphology and tau pathology.

Authors:  Alberto Serrano-Pozo; Christopher M William; Isidro Ferrer; Emmanuelle Uro-Coste; Marie-Bernadette Delisle; Claude-Alain Maurage; Christoph Hock; Roger M Nitsch; Eliezer Masliah; John H Growdon; Matthew P Frosch; Bradley T Hyman
Journal:  Brain       Date:  2010-03-31       Impact factor: 13.501

8.  Four-dimensional microglia response to anti-Aβ treatment in APP/PS1xCX3CR1/GFP mice.

Authors:  Monica Garcia-Alloza; Laura A Borrelli; Diana H Thyssen; Suzanne E Hickman; Joseph El Khoury; Brian J Bacskai
Journal:  Intravital       Date:  2013-04-01

Review 9.  Multiphoton in vivo imaging of amyloid in animal models of Alzheimer's disease.

Authors:  Jinghui Dong; Raquel Revilla-Sanchez; Stephen Moss; Philip G Haydon
Journal:  Neuropharmacology       Date:  2010-04-14       Impact factor: 5.250

10.  Aβ-mediated spine changes in the hippocampus are microtubule-dependent and can be reversed by a subnanomolar concentration of the microtubule-stabilizing agent epothilone D.

Authors:  Lorène Penazzi; Christian Tackenberg; Adnan Ghori; Nataliya Golovyashkina; Benedikt Niewidok; Karolin Selle; Carlo Ballatore; Amos B Smith; Lidia Bakota; Roland Brandt
Journal:  Neuropharmacology       Date:  2016-01-06       Impact factor: 5.250

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.